Answers are grounded in this paper and cite their sources.
Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). At a 10(-4) M concentration, GTP and GDP decreased specific binding of 0.4 nM [3H]-8-OH-DPAT to 47 +/- 4 and 61 +/- 1% of control values respectively. This nucleotide effect was significantly greater (P less than 0.005) than observed at total 5-HT1 binding sites labeled by 1.5 nM [3H]-5-HT. GMP and adenine nucleotides had a minimal effect on [3H]-8-OH-DPAT binding at concentrations less than 10(-3) M. Saturation experiments demonstrated that 10(-4) M GTP increased the KD of [3H]-8-OH-DPAT for 5-HT1A binding sites (0.79 to 2.7 nM) without changing the number of binding sites (1.98 to 1.93 pmoles/g tissue). The Ki values of classic and novel putative 5-HT agonists were increased 2- to 4-fold in the presence of 10(-4) M GTP. Affinities of 5-HT antagonists for the [3H]-8-OH-DPAT site were not affected by the addition of 10(-4) M GTP to the binding assay.
No takes yet. Share an insight, caveat, or question.
Schlegel et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: